Literature DB >> 19043011

Bronchial fistulae in ARDS patients: management with an extracorporeal lung assist device.

M Hommel1, M Deja, V von Dossow, K Diemel, C Heidenhain, C Spies, S Weber-Carstens.   

Abstract

Patients with bronchial tree lesions feature, in particular, a high risk for developing bronchial fistulae after surgical repair when the clinical situation is complicated by acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and mechanical ventilation is needed. The current authors hypothesised that extracorporeal carbon dioxide removal would significantly decrease inspiratory airway pressures, thus promoting the protection of surgical bronchial reconstruction. Four patients were studied after surgical reconstruction of bronchial fistulae in whom ALI/ARDS developed and mechanical ventilation with positive end-expiratory pressure was required. Gas exchange, tidal volumes, airway pressures, respiratory frequency, vasopressor and sedation requirements were analysed before and after initiation of a pumpless extracorporeal lung assist device (pECLA; NovaLung, Talheim, Germany). Initiation of pECLA treatment enabled a reduction of inspiratory plateau airway pressures from 32.4 to 28.6 cmH(2)O (3.2 to 2.8 kPa), effectively treated hypercapnia (from 73.6 to 53.4 mmHg (9.8 to 7.1 kPa)) and abolished respiratory acidosis (from pH 7.24 to 7.41). All patients survived and were discharged to rehabilitation clinics. In patients after surgical bronchial reconstruction that was complicated by acute lung injury/acute respiratory distress syndrome, use of pumpless extracorporeal carbon dioxide removal was safe and efficient. Initiation of a pumpless extracorporeal lung assist device enabled a less invasive ventilator management, which may have contributed to healing of surgical bronchial repair.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19043011     DOI: 10.1183/09031936.00021008

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  [Interventional lung assist membrane ventilator. Successful use despite heparin-induced thrombocytopenia type II].

Authors:  J Lange; D Knüttgen; E Stoelben; U Bauerfeind; F Wappler; S G Sakka
Journal:  Anaesthesist       Date:  2010-12-25       Impact factor: 1.041

2.  Evaluation of a pumpless lung assist device in hypoxia-induced pulmonary hypertension in juvenile piglets.

Authors:  George T El-Ferzli; Joseph B Philips; Arlene Bulger; Namasivayam Ambalavanan
Journal:  Pediatr Res       Date:  2009-12       Impact factor: 3.756

3.  Treatment of Bronchopleural and Alveolopleural Fistulas in Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation, a Case Series and Literature Review.

Authors:  Mazen F Odish; Jenny Yang; George Cheng; Cassia Yi; Eugene Golts; Michael Madani; Travis Pollema; Robert L Owens
Journal:  Crit Care Explor       Date:  2021-05-14

4.  Effects of pumpless extracorporeal lung assist on hemodynamics, gas exchange and inflammatory cascade response during experimental lung injury.

Authors:  Zhihai Ju; Jinhui Ma; Chen Wang; Jie Yu; Yeru Qiao; Feilong Hei
Journal:  Exp Ther Med       Date:  2017-12-18       Impact factor: 2.447

5.  Successful Rescue Therapy with Pumpless Extracorporeal Carbon Dioxide Removal in a Patient with Persistent Air Leakage due to Empyema.

Authors:  Jaeyoung Cho; Yeon Joo Lee; Jae-Ho Lee; Choon-Taek Lee; Young-Jae Cho
Journal:  Korean J Crit Care Med       Date:  2016-11-14

6.  Empyema with fistula successfully treated with a comprehensive approach including bronchial blocker and embolization receiving veno-venous extracorporeal membrane oxygenation.

Authors:  Kijong Shin; Toru Hifumi; Ryosuke Tsugitomi; Shutaro Isokawa; Masato Shimizu; Norio Otani; Shinichi Ishimatsu
Journal:  Acute Med Surg       Date:  2021-02-09

7.  Extracorporeal life support for acute respiratory distress syndromes.

Authors:  Don Hayes; Joseph D Tobias; Jasleen Kukreja; Thomas J Preston; Andrew R Yates; Stephen Kirkby; Bryan A Whitson
Journal:  Ann Thorac Med       Date:  2013-07       Impact factor: 2.219

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.